

Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

BIO/SECL/AJ/2023-24/157

February 8, 2024

То,	To,
The Manager	The Manager
BSE Limited	National Stock Exchange of India Limited
Department of Corporate Services	Corporate Communication Department
Phiroze Jeejeebhoy Towers,	Exchange Plaza, Bandra Kurla Complex
Dalal Street, Mumbai – 400 001	Mumbai – 400 050
Scrip Code - 532523	Scrip Symbol – Biocon

Subject: Press Release on financial results for the quarter and nine months ended December 31, 2023.

Dear Sir/Madam,

Please find enclosed the press release titled **"Biocon Q3FY24 Revenue at Rs 4,519 Cr, Up 50%; Biosimilars Up 65%; Research Services Up 9%; EBITDA at Rs 1,492 Cr, Up 106%; Net Profit at Rs 660 Cr; Pre-Paid USD 200 Mn towards Debt Reduction**" pertaining to the un-audited consolidated financial results of Biocon Limited for the quarter and nine months ended December 31, 2023.

The above information will also be available on the website of the Company at <u>www.biocon.com</u>.

Kindly take the above information on record and acknowledge.

Thanking You,

Yours faithfully,

For Biocon Limited

Mayank Verma Company Secretary & Compliance Officer Membership No.: ACS 18776

Enclosed: Press Release and Fact Sheet






PRESS RELEASE

Biocon Q3FY24 Revenue at Rs 4,519 Cr, Up 50%; Biosimilars Up 65%; Research Services Up 9%; EBITDA at Rs 1,492 Cr, Up 106%; Net Profit at Rs 660 Cr Pre-Paid USD 200 Mn towards Debt Reduction

Bengaluru, Karnataka, India: February 8, 2024:

Biocon Ltd (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, today announced its consolidated financial results for the fiscal third quarter ended December 31, 2023.







Leadership Comments

BIOCON GROUP

"Biocon delivered Consolidated Revenue of Rs 4,519 crore for Q3FY24, driven by 65% growth in Biosimilars and 9% growth in Research Services. Consolidated EBITDA at Rs 1,492 crore grew by 106%. Net Profit, boosted by other income, stood at Rs 660 crore.

"A key milestone this quarter was the successful conclusion of the transition of the acquired business by Biocon Biologics and a pre-payment of ~USD 200 million towards the acquisitionrelated debt reduction. Steady market shares for key biosimilars in the U.S. and EU were complemented by the Emerging Markets performance which saw a number of new product launches and tender wins.

"We continue to make steady progress towards strengthening the foundation for a sustainable growth across all three business segments."

-- Kiran Mazumdar Shaw, Executive Chairperson, Biocon and Biocon Biologics

BIOCON GENERICS

"The Generics business delivered 4% sequential revenue growth in the third quarter, driven by higher API sales.

"The year-on-year performance, however, was muted on account of continued pricing pressure that impacted customer offtake in our API business, compared to the previous fiscal. This was partially offset by growth in our Generic Formulations portfolio. While we expect pricing pressure in the API business to persist, we continue our focus on driving cost and execution efficiencies throughout the business, to mitigate future impact.

"We received a tentative approval of our ANDA for Dasatinib tablets from the U.S. FDA recently, which reinforces our strategy to vertically integrate complex, difficult-to-make products."

-- Siddharth Mittal, CEO & Managing Director, Biocon Limited

BIOCON BIOLOGICS

"Biocon Biologics successfully completed the complex, accelerated integration of the entire acquired business across 120+ countries, one year ahead of plan, transforming us into a unique, fully integrated, 'lab-to market' leading global biosimilars player. Our focus has been on preserving value, business continuity and ensuring a seamless experience for our patients, customers, and partners across the world. This success is a testament to the hard work and dedication of our team and advisors.

"During the quarter, the business delivered 65% year-on-year growth as we continued to see robust demand for our products with market shares increasing across geographies. We onboarded new customers and won several key tenders."

-- Shreehas Tambe, CEO & Managing Director, Biocon Biologics Limited





SYNGENE

"Syngene reported a revenue growth of 9% year-on-year in the third quarter on the back of good performance by Dedicated Centers, Development and Manufacturing divisions. Though demand in our Discovery Services division was impacted during the quarter by headwinds in the U.S. biotech segment, we are starting to see early signs of funding levels stabilizing. Our business model remains resilient, and we are continuing to invest in scientific capabilities and important enterprise projects as industry fundamentals for pharma outsourcing remain positive for the medium-to-long term."

-- Jonathan Hunt, CEO & Managing Director, Syngene

FINANCIAL HIGHLIGHTS (CONSOLIDATED): Q3FY24

In Rs Crore

Particulars	Q3FY24	Q3FY23	YoY (%)
INCOME			
Generics	703	760	- 7%
Biosimilars	2,483	1,507	65%
Novel Biologics	-	-	
Research services	854	786	9%
Inter-segment	-86	-112	-23%
Revenue from operations [#]	3,954	2,941	34%
Other income ^{\$}	565	79	615 %
Total Revenue	4,519	3,020	50%
Net R&D Expenses	329	337	-2%
Gross R&D Spend	332	365	-9%
EBITDA	1,492	723	106%
EBITDA Margins	33%	24%	
Core EBITDA*	983	1,069	-8%
Core EBITDA Margins*	27%	36%	
PBT (before Exceptional Items^)	787	246	220%
Net Profit (before Exceptional Items^)	644	140	360%
Net Profit Margin (before Exceptional Items^)	14%	5%	
Net Profit^	660	-42	
Net Profit Margin	15%	-1%	

Figures above are rounded off to the nearest Crore; % based on absolute numbers.

[#] Includes income from the divesture of two non-core business assets of Biocon Biologics' Branded Formulations India business amounting to Rs 350 crore and Licensing income.

*Core EBITDA is EBITDA net of R&D expense, licensing, forex, dilution/fair valuation gain in Bicara, sale of noncore BFI assets and mark-to-market movement on investments.

Notes to financials above:

^{\$}Other income for Q3FY24 includes a gain of Rs 456 crore mainly from the fair valuation of Biocon's holding in Bicara Therapeutics, resulting from Bicara's Series C financing.

^ Exceptional items during Q3 FY24 amount to a net gain of Rs 21 crore. Net of tax and minority interest, exceptional gains during Q3FY24 amounted to Rs 16 crore, resulting in a Net Profit of Rs 660 crore. Please refer to Note 17: Exceptional Items in the published Financial Results.





Financial Commentary: Q3FY24

Consolidated Revenue for Q3FY24 grew **50%** year-on-year (YoY) to **Rs 4,519 crore**. This growth was supported by income from the divesture of two non-core business assets of Biocon Biologics' Branded Formulations India business amounting to Rs 350 crore and a gain of Rs 456 crore from Biocon's stake dilution in Bicara Therapeutics.

EBITDA for the quarter increased by **106%** to **Rs 1,492** crore, representing an **EBITDA margin of 33%** versus 24% in the same period last year.

Depreciation, amortisation, and interest increased by Rs 260 crore over last year. This is primarily related to the biosimilars business acquisition cost.

Net R&D investments for the quarter were **Rs 329 crore**, representing 11% of revenue ex-Syngene.

Core EBITDA at Rs 983 crore, represents core operating margins of 27%.

Profit Before Tax and exceptional items stood at Rs 787 crore.

Reported **Net Profit** for the quarter stood at **Rs 660 crore** versus a Net Loss of Rs 42 crore in the same quarter of the previous year.

CORPORATE HIGHLIGHTS

Board Announcements

Biocon Biologics Limited

Nicholas Robert Haggar has been appointed as an **Independent Director** on the Board of Biocon Biologics Limited for a period of three years with effect from February 6, 2024.

He has over 30 years of experience in leading and building pharmaceutical and healthcare enterprises and has been successfully guiding innovation and increasing access to medicines with deep commitment to patients, compliance, quality and sustainability. He has been a part of Biocon Limited's Board as an Additional Director, since September 2023.

Nicholas has held the position of CEO, Zentiva SA; CEO, Insud Pharma SL; President of Medicines for Europe; and Regional Director, Sandoz. He is currently the CEO & Founder of HealthQube Ltd and a Non-Executive Director of Zentiva.

Management Announcements

Biocon Limited

Nitin Prabhakar Shenoy has been appointed as Head of IT & Digital Transformation, Biocon Limited. Nitin brings with him nearly three decades of experience in IT operations, SAP delivery including support, implementation and pre-sales, assessment and design of MES systems.





Awards & Recognitions

ESG Practices: Biocon (including Biocon Biologics)

- **Biocon** has been included in the **S&P Global Sustainability Yearbook 2024** for the **second year** in a row, based on its 2023 Corporate Sustainability Assessment.
- The Company has improved its **S&P Global ESG Score** to **63** from 52 previously.
- **Biocon** continues to be a member of the **DJSI Emerging Markets Index** for the **third year** in a row.
- **Biocon Biologics** has been recognized by the 'Life at Work Awards' as one of the Top **3** companies for Sustainability and Diversity, Equity & Inclusion (DEI) in Malaysia.

Intellectual Property Strategy

- Biocon Biologics has been included in the ASIA IP ELITE list for 2023 by IAM (Intellectual Asset Management), the world's biggest IP publication.
- Biocon Biologics also won the CII's Special Appreciation IP Award 2023 at the 9th International Conference on Intellectual Property Rights (IPR).

Operational & Quality Excellence

- Biocon won the prestigious Jury Champion Award in the 'Breakthrough Category' at the 46th CII National Kaizen Competition and two awards at QCFI's 37th National Convention on Quality Concept 2023.
- Biocon Biologics won 3 awards in the 4th National Challenger's Trophy event as part of the 46th CII National Kaizen Competition and one award at QCFI's 37th National Convention on Quality Concept 2023.
- These awards recognize the best industry practices for quality and operational excellence.

People Practices

 Biocon Biologics has been recognized among the '100 Best Companies for Women' and 'Top 100 Exemplars of Inclusion' in India for the sixth time in a row by Avtar & Seramount.

Business Highlights

GENERICS: APIs & Generic Formulations

• Q3FY24 Revenue at Rs 703 Crore down by 7% (YoY) from Rs 760 Crore in Q3FY23.

Business Performance

Performance during the quarter saw sequential revenue growth, led by higher API sales. The subdued year-on-year performance was due to pricing pressure in the API business that impacted customer offtake, which was partially offset by sustained growth across most of the Generic Formulation products.

The Company received its first Generic Formulations approval in China for **Mycophenolate Sodium** (MPS), an immunosuppressant used to help prevent organ transplant rejection. This paves the way for the Company's finished dosage formulations foray into China, a key strategic market.





Biocon also received a tentative approval for **Dasatinib** tablets, for 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg strengths, from the U.S. Food and Drug Administration (FDA), recently. Dasatinib is indicated for use in the treatment of Philadelphia chromosome positive chronic myeloid leukemia in adults. It is also used to treat Philadelphia chromosome positive acute lymphoblastic leukemia in adults with resistance or intolerance to prior therapy.

TGA Australia completed an inspection of the Company's API facility in Visakhapatnam with no critical observations. The API facility at Hyderabad also underwent a remote inspection by Cofepris, Mexico, with two observations, for which responses have been submitted.

Post completion of process validation at the Company's greenfield immunosuppressants facility in Visakhapatnam, the site obtained a Certification of Suitability (CEP) from the European Directorate for the Quality of Medicines (EDQM). The Company expects the site to be inspected and qualified by other regulatory authorities during the next fiscal, enabling commercialization of its products across geographies.

Process validation at the Company's large volume peptides facility at Bengaluru was successfully completed during the quarter. At the Synthetic API facility in Hyderabad, process validation was initiated.

NOVEL BIOLOGICS

Biocon's Boston-based associate **Bicara Therapeutics** closed a USD 165 million **Series C** financing in December 2023, led by TPG and Braidwell. With this, USD 355 million has been raised to date from a syndicate of biotech investors, with all Series B investors participating in this round of financing.

As a result, the Company has recorded a gain of Rs 456 crore, arising from dilution of Biocon's shareholding to 14% and loss of significant influence over Bicara. Hence it will no longer be an 'associate company' of the Biocon Group.

BIOSIMILARS: Biocon Biologics Limited (BBL)

- Q3FY24 Revenue at Rs 2,483 Crore, up 65% (YoY) from Rs 1,507 Crore in Q3FY23.
- Reduced the acquisition debt by USD 200 million.
- Preserved, consolidated and built business post successful integration.
- Served 5.5+ million patients (MAT December 2023) ##

##12-month moving annual patient population (January 2023 to December 2023)

Business Performance

Biocon Biologics reported a YoY growth of 65% for Q3FY24 with revenue at Rs 2,483 crore, demonstrating its ability to maintain its growth momentum while completing the complex and accelerated integration of the acquired biosimilars business. In this quarter, Biocon Biologics successfully completed its transition to a fully integrated, 'lab-to-market' global biosimilars enterprise with a presence across 120+ countries.





During this time of rapid operational transformation, the Company successfully maintained business continuity while seamlessly serving patients, partners, and customers worldwide and securing new customers and tenders in both Advanced and Emerging Markets.

EBITDA for the quarter reported a growth of 98% at Rs 714 crore, representing an EBITDA margin of 29%.

During the quarter, Net R&D investments stood at Rs 265 crore, representing 11% of Biocon Biologics' revenue for the quarter, reflecting the advancement of our biosimilars pipeline.

Core EBITDA at Rs 587 crore, with Core EBITDA margins at 28%, were impacted on account of a series of transition related expenses and one-off costs.

Biocon Biologics prepaid ~USD 200 million towards reducing the acquisition-related debt during the quarter.

Advanced Markets

North America@

Biocon Biologics sharpened its focus on a self-led commercial model in North America, following the seamless integration of people and business operations.

The Company's products maintained momentum and showed resiliency in a dynamic market in the immediate quarter post the integration of the acquired biosimilars business. It expanded market access across all therapeutic segments in the U.S., making strides in insulins and oncology portfolios and securing several immunology formulary wins.

Biocon Biologics drove an uptick in sales of unbranded bGlargine with a closed-door pharmacy network even as unbranded bGlargine along with Semglee[®] held market share steady at ~12%.

Fulphila[®] (bPegfilgrastim) maintained ~18% market share in the U.S. The Company won **three** new contracts, including a sole-source contract from a large group purchasing organization (GPO) for the pre-filled syringe presentation of its bPegfilgrastim. **Ogivri**[®] (bTrastuzumab), which reported a market share of ~12% in U.S., secured **three** new contracts, including a large GPO agreement.

In line with the improvement in market adoption of biosimilar Adalimumab in the U.S., Biocon Biologics successfully secured **two** contracts for its unbranded **bAdalimumab**, both commencing in February 2024.

Europe and JANZ[&]

By the end of Q3FY24, Biocon Biologics successfully integrated the acquired biosimilars business across more than **30 countries** in Europe as well as Japan, Australia and New Zealand (JANZ).





In Europe, the market share for **Fulphila**[®] grew to 8% in Q3. Existing in-market products such as **Ogivri**[®], **Abevmy**[®], and **Hulio**[®] held steady market shares at 6% each across the region. In Australia, **Ogivri**[®] holds a strong ~16% market share.

The Company has partnered with Sandoz granting it exclusive rights to promote, sell and distribute "Adalimumab BS for subcutaneous injection [FKB]" *** in Japan.

Emerging Markets (EMs)

Following the successful transition of **85+ Emerging Markets** to Biocon Biologics, the Company has augmented its focus on nine self-led markets and all other partner-led countries. The Company also onboarded new partners for its products in many countries in APAC, LATAM and AFMET.

In Q3FY24, Biocon Biologics ensured business continuity in both partner- and self-led markets. It pursued new growth avenues by winning several tenders for its products, including for the acquired business in territories like Tunisia, Libya and Ukraine, in addition to obtaining numerous approvals for key biosimilars across EMs.

With the launch of **Abevmy**[®] (bBevacizumab), Biocon Biologics has initiated its 'direct to market' journey in **Brazil**, which is the largest market for this molecule in LATAM. Innovator sales for Bevacizumab in Brazil are over USD 175 million^{^^}. The Company is seeing positive traction for Abevmy[®] despite the presence of multiple players in the market.

Expanding Insulins Access

Biocon Biologics is addressing the challenge of insulin inequity through its **Market Access** programs in several countries. In Q3FY24, the Company supplied its **bGlargine** at subsidized rates for the benefit of ~100 young people with Type 1 diabetes in Myanmar.

The Company also donated 12,500 **bGlargine** pens and 1,000 vials to the U.S.-based 'Insulin for Life', a non-profit organization that provides donated supplies to partner clinics and hospitals. It addresses the needs of patients with diabetes in LMICs (low- and middle-income countries) around the world.

Regulatory & Clinical Updates

Key highlights include initiation of global Phase 3 clinical trials for **bPertuzumab** and a marketing authorization approval for **YESAFILI**[®] (bAflibercept) from MHRA, UK.

[®] North America: Market shares based on IQVIA November 2023 data.

[&] Europe & JANZ: Market shares based on IQVIA Q3 CY2023 data.

^{****}Fujifilm Kyowa Kirin Biologics Co. Ltd. is a Marketing Authorization Holder in Japan.

^{***} Emerging Markets: Bevacizumab Innovator Sales in Brazil; Source: FMB+NRC Reference MAT August 2023.





RESEARCH SERVICES: Syngene

• Q3FY24 Revenue at Rs 854 Crore, up 9% (YoY) from Rs 786 Crore in Q3FY23.

Business Performance

In Q3FY24, the Research Services business delivered positive performances in Development and Manufacturing Services divisions as well as in the Dedicated Centers. Syngene's performance in Discovery Services was impacted by the slowdown of funding in the global biotech ecosystem. In Manufacturing Services, the Company continued to make good progress on the long-term biologics manufacturing partnership with Zoetis. Overall, the Company maintained healthy EBITDA margins of 30%.

The acquisition of the biologics facility from Stelis Biopharma Ltd has been completed. Once operational, it will add to both drug substance and drug product capabilities of Syngene.

The Company also added a biologics assay capability at the Hyderabad campus to complement the existing Drug Metabolism and Pharmacokinetics (DMPK) and Compound Management facilities.

Enclosed: Fact Sheet – with Financials as per IND-AS

About Biocon Limited:

Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development. Website: www.biocon.com; Follow-us on Twitter: @bioconlimited for company updates.

Biocon Biologics Limited (BBL), a subsidiary of Biocon Ltd., is a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives by enabling affordable access to high quality biosimilars for millions of patients worldwide. It is leveraging cuttingedge science, innovative tech platforms, global scale manufacturing capabilities and world-class quality systems to lower costs of biological therapeutics while improving healthcare outcomes. BBL has integrated the acquired global biosimilars business of its long-standing partner Viatris, which is a historic milestone in its value creation journey. Biocon Biologics has commercialized eight biosimilars in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan. The Company has a pipeline of 20 biosimilar assets across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. It has many 'firsts' to its credit in the biosimilars industry. As part of its environmental, social and governance (ESG) commitment, BBL is advancing the health of patients, people, and the planet to achieve key UN Sustainable Development Goals (SDGs). Website: www.bioconbiologics.com; Follow us on Twitter: @BioconBiologics and LinkedIn: <u>Biocon Biologics</u> for company updates.





FOR MORE INFORMATION			
MEDIA	INVESTORS		
Biocon Group & Biocon Biologics	Biocon		
Seema Ahuja	Saurabh Paliwal		
Global Head of Corporate Brand	Head - Investor Relations		
& Communications			
	+91 95383 80801		
+91 99723 17792	⊠ <u>saurabh.paliwal@biocon.com</u>		
🖂 seema.ahuja@biocon.com			
Biocon			
For Generics business			
Calvin Printer			
Head - Corporate Communications			
+91 70329 69537			
calvin.printer@biocon.com			


Earnings Call

The management of the Company will host an Earnings Call on 9th February 2024 at 09:00 hrs, over a Zoom Webinar, where the senior management will discuss the Company's performance and answer questions from participants. Details of the Zoom webinar is given below as well as on the Company website <u>www.biocon.com</u> under Investors >> Financial Calendar >> Earnings Call for the period ended December 31, 2023. Transcript of the conference call will be uploaded on the Company website in due course.

Zoom Webinar Details	
Date	February 9, 2024
Time	09:00 – 10:30 IST (UTC +05:30)
Join Zoom Webinar	Click here to attend earnings call

Forward-Looking Statements: Biocon

This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Biocon and its subsidiaries/ associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian and global biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither Biocon, nor our Directors, or any of our subsidiaries/associates assume any obligation to update any particular forward-looking statement contained in this release.



BIOCON LIMITED (CONSOLIDATED) PROFIT & LOSS STATEMENT (Rs. Cro			
Particulars	Q3 FY 24	Q3 FY 23	Variance %
INCOME			
Generics	703	760	-7%
Biosimilars	2,483	1,507	65%
Novel Biologics	-	-	0%
Research services	854	786	9%
Inter-segment	(86)	(112)	-23%
Revenue from operations #	3,954	2,941	34%
Other income	565	79	619%
TOTAL REVENUE	4,519	3,020	50%
EXPENDITURE			
Material & Power costs	1,320	1,090	21%
Staff costs	555	520	7%
Research & Development expenses*	329	337	-2%
Other expenses	823	349	136%
Manufacturing, staff & other expenses	3,027	2,297	32%
EBITDA	1,492	723	106%
Interest & Finance charges	267	120	122%
Depreciation & Amortisation	415	301	38%
Share of loss / (profit) in JV / Associate, net	24	56	-57%
PBT	787	246	220%
Exceptional item	21	(271)	-
PBT	808	(25)	-3269%
Taxes	53	46	16%
Taxes on exceptional item	2	(50)	-105%
NET PROFIT BEFORE MINORITY INTEREST	753	(21)	-3739%
Minority interest	90	60	49%
Minority interest on exceptional item	3	(39)	-
NET PROFIT FOR THE PERIOD	660	(42)	-1679%
EPS Rs.	5.5	(0.3)	
NET PROFIT BEFORE EXCEPTIONAL ITEM	644	140	360%
Exceptional item, net of taxes	16	(182)	-109%
	660	(182)	-1679%
NET PROFIT FOR THE PERIOD	660	(42)	-10/9%
# Licensing Income	5	11	
* Gross Research & Development expenses	332	365	

BIOCON LIMITED (CONSOLIDATED) PROFIT & LOSS STATEMENT (Rs. Crores)			
Particulars	Q3 FY 24	Q2 FY 24	Variance %
INCOME			
Generics	703	676	4%
Biosimilars	2,483	1,969	26%
Novel Biologics	-	-	0%
Research services	854	910	-6%
Inter-segment	(86)	(93)	-79
Revenue from operations #	3,954	3,462	14%
Other income	565	158	258%
TOTAL REVENUE	4,519	3,620	25%
EXPENDITURE			
Material & Power costs	1,320	1,227	8%
Staff costs	555	530	5%
Research & Development expenses*	329	264	25%
Other expenses	823	700	189
Manufacturing, staff & other expenses	3,027	2,721	11%
EBITDA	1,492	900	66%
Interest & Finance charges	267	248	8%
Depreciation & Amortisation	415	389	6%
Share of loss / (profit) in JV / Associate, net	24	24	0%
PBT BEFORE EXCEPTIONAL ITEM	787	238	230%
Exceptional item, Net	21	(24)	-100%
PBT	808	214	277%
Taxes	53	46	15%
Taxes on exceptional item	2	(4)	-155%
NET PROFIT BEFORE MINORITY INTEREST	753	173	336%
Minority interest	90	51	77%
Minority interest on exceptional item	3	(4)	
NET PROFIT FOR THE PERIOD	660	126	425%
EPS Rs.	5.5	1.0	
NET PROFIT BEFORE EXCEPTIONAL ITEM	644	142	355%
Exceptional item	16	(16)	
NET PROFIT FOR THE PERIOD	660	126	425%
# Licensing Income	5	6	
* Gross Research & Development expenses	332	278	

BIOCON LIMITED (CONSOLIDATED) PROFIT & LOSS STATEMENT (Rs. Crores)			
Particulars	9M FY 24	9M FY 23	Variance %
INCOME			
Generics	2,080	2,020	3%
Biosimilars	6,466	3,481	86%
Novel Biologics	-	-	0%
Research services	2,572	2,199	17%
Inter-segment	(280)	(299)	-6%
Revenue from operations #	10,839	7,400	46%
Other income	817	221	270%
TOTAL REVENUE	11,656	7,621	53%
EXPENDITURE			
Material & Power costs	3,870	2,735	42%
Staff costs	1,605	1,475	9%
Research & Development expenses*	908	777	17%
Other expenses	2,073	898	131%
Manufacturing, staff & other expenses	8,456	5,886	44%
EBITDA	3,200	1,736	84%
Interest & Finance charges	747	171	338%
Depreciation & Amortisation	1,162	749	55%
Share of loss / (profit) in JV / Associate, net	82	127	100%
PBT BEFORE EXCEPTIONAL ITEM	1,209	689	75%
Exceptional item, Net	(3)	(288)	-
PBT	1,206	401	201%
Taxes	133	118	13%
Tax expense on adoption of new tax regime - exceptional	-	107	
Taxes on exceptional item	(2)	(53)	-100%
NET PROFIT BEFORE MINORITY INTEREST	1,075	229	370%
Minority interest	189	119	59%
Minority interest on exceptional item	(1)	(40)	-
NET PROFIT FOR THE PERIOD	887	150	493%
EPS Rs.	7.4	1.2	
NET PROFIT BEFORE EXCEPTIONAL ITEM	886	453	96%
Exceptional item, net of taxes	1	(196)	
Tax expense on adoption of new tax regime - exceptional	-	(107)	
NET PROFIT FOR THE PERIOD	887	150	493%
# Licensing Income	178	31	
* Gross Research & Development expenses	934	839	

BIOCON LIMITED (CONSOLIDATED) BALANCE SHEET

Particulars	Dec 31, 2023	(Rs Crores March 31, 2023
Farticulars	Dec 31, 2023	Widtell 51, 2025
ASSETS		
Non-current assets		
(a) Property, plant and equipment	7,438	7,277
(b) Capital work-in-progress	3,982	2,588
(c) Right-of-use assets	482	258
(d) Goodwill	16,343	16,130
(e) Other intangible assets	6,434	5,796
(f) Intangible assets under development	3,827	4,730
(g) Investment in associates and a joint venture	2	138
(h) Financial assets		
Investments	664	60
Derivative assets	242	14
Other financial assets	209	1,08
(i) Income tax asset, net	462	354
(j) Deferred tax asset, net	270	30:
(k) Other non-current assets	348	298
Non-current assets	40,703	39,709
Current assets		
(a) Inventories	5,023	4,24
(b) Financial assets		
Investments	1,927	1,32
Trade receivables	4,678	3,57
Cash and cash equivalents	1,024	1,32
Other bank balances	795	1,07
Derivative assets	186	70
Other financial assets	246	132
(c) Other current assets	949	588
Current assets	14,828	12,334
TOTAL - ASSETS	55,531	52,043

BIOCON LIMITED (CONSOLIDATED)		
BALANCE SHEET		
		(Rs Crores
Particulars	Dec 31, 2023	March 31, 2023
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	600	600
(b) Other equity	19,142	17,267
Equity attributable to owners of the Company	19,742	17,867
Non-controlling interests	5,391	4,622
Total Equity	25,133	22,489
Non-current liabilities		
(a) Financial liabilities		
Borrowings	13,181	15,291
Lease liabilities	449	209
Derivative liabilities	127	26
Other financial liabilities	2,440	4,620
(b) Provisions	107	227
(c) Deferred tax liability, net	331	382
(d) Other non-current liabilities	326	290
Non-current liabilities	16,961	21,043
Current liabilities		
(a) Financial liabilities		
Borrowings	2,872	2,480
Lease liabilities	81	39
Trade payables	6,129	3,983
Derivative liabilities	18	55
Other financial liabilities	3,454	467
(b) Provisions	193	149
(c) Income tax liability, net	276	225
(d) Other current liabilities	414	1,109
Current liabilities	13,437	8,511
TOTAL - EQUITY AND LIABILITIES	55,531	52,043